A Study Of Hsp90 Inhibitor At13387 Alone And In Combination With Crizotinib In The Treatment Of Non-Small Cell Lung Cancer (Nsclc)
Posted Date: May 15, 2019
- Investigator: Nagla Abdel Karim
- Type of Study: Drug
This study is designed to evaluate AT13387 (the study drug) alone or in combination with Crizotinib in subjects with Non-small cell lung cancer (NSCLC). The study drug that will be used in this study, (AT13387), is investigational. This means it has not been approved for use by the United States
Criteria:
To Be Eligible For The Study You Must Have Non-Small Cell Lung Cancer (Nsclc).
Keywords:
Cancer, Lung, At13387-05, Combination, Nsclc
For More Information:
Uc Cancer Center
513-584-7698
kastla@ucmail.uc.edu